Overview

• Zepbound cuts risk of heart failure-related complications by 38% compared to placebo in a two-year study.
• The drug also alleviates symptoms like shortness of breath, fatigue, and irregular heartbeat.
• Participants experienced an average weight loss of 15.7% during the trial.
• Eli Lilly plans to submit the trial results to the FDA and other regulators later this year.
• The company anticipates the end of the current Zepbound shortage 'very soon,' according to the CEO.